A2A/A2B Receptor Antagonist Scaffolds for Tumor Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for potent and selective inhibitors of the A2a and/or A2b adenosine receptors to address the immunosuppressive effects of adenosine in tumor microenvironments, enhance anti-tumor immune responses, and treat various cancers.
Innovation Solution
Development of novel compounds with structures in accordance with Formula (IA) or Formula (IB) that act as inhibitors of the adenosine A2a and/or A2b receptors, which can be administered alone or in combination with other therapeutic agents to treat diseases mediated by these receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If adenosine signaling through A2a and A2b receptors is activated, then tissue protection during inflammatory responses is achieved, but tumor growth is promoted and anti-tumor immune responses are inhibited
Solution Approach 1:
The patent converts the harmful immunosuppressive effect of adenosine signaling into a beneficial therapeutic approach by using selective A2a and A2b receptor antagonists. These antagonists block the harmful adenosine-receptor interactions that promote tumor growth and suppress immunity, while preserving the beneficial tissue protection functions through selective targeting. The result is transformed harm into benefit by selectively inhibiting the harmful pathway without completely blocking adenosine signaling.
Solution Approach 2:
The patent applies local quality by developing receptor-selective antagonists that differentially target A2a and A2b receptors. The compounds are designed with specific molecular structures (Formulas IA and IB with defined substituents) that confer selective affinity for particular receptor subtypes. This allows the therapy to exert different effects at different locations: blocking A2a receptors to enhance anti-tumor immunity while potentially preserving A2b-mediated tissue protection functions, thereby addressing the harmful effects locally without compromising beneficial systemic functions.
2Reliability
If A2a and A2b adenosine receptor antagonists are used to enhance anti-tumor immune responses, then tumor-specific T-cell responses are improved, but potential off-target effects and safety issues arise
Solution Approach 1:
The patent achieves local quality through structure-based receptor selectivity. The compounds are designed with specific molecular features (substituents at defined positions in Formulas IA and IB) that confer selective binding to A2a and A2b receptors over other adenosine receptors (A1, A3) and off-target proteins. This selective local interaction minimizes off-target effects while maximizing the desired anti-tumor immune enhancement through A2a/A2b-specific blocking.
Solution Approach 2:
The patent applies parameter changes by systematically varying molecular parameters (substituents R1-R6, n values, stereochemistry) to optimize the pharmacological profile of each compound. By adjusting these structural parameters, the patent fine-tunes receptor affinity, selectivity, and pharmacokinetic properties to enhance anti-tumor efficacy while minimizing off-target effects and toxicity, thereby resolving the contradiction between effectiveness and safety.
3Reliability
If selective A2a/A2b receptor antagonists are developed to treat cancer, then therapeutic efficacy is improved, but compound complexity and synthesis difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core scaffold (pyrimidine or pyrazine ring system) and variable substituent groups (R1-R6). This modular segmentation allows independent optimization of each segment for specific properties: the core provides receptor binding pharmacophore while substituents can be adjusted for pharmacokinetics, selectivity, and safety. This reduces overall synthesis complexity compared to designing entirely new molecules, as the segmented approach uses established building blocks.
Solution Approach 2:
The patent achieves universality by creating a family of compounds (Formulas IA and IB with multiple substituent options) that share a common core structure and binding mechanism. This universal scaffold can be applied across multiple tumor types and patient populations, providing a platform for versatile therapy. The multi-functionality of the core structure (binding to A2a and A2b receptors simultaneously or selectively) reduces the need for entirely separate drug candidates, thereby reducing overall development complexity while maintaining high efficacy.
Data Source
AI summary
In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB):and pharmaceutically acceptable salts thereof, wherein, R1, n, R2, and R3 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.